Subscribe
Golden Shrimp / Shutterstock.com
5 September 2024NewsAmericasMarisa Woutersen

AstraZeneca unit draws line under Samsung dispute

AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Samsung Biologics faces suit from Amgen over bone biosimilars
15 August 2024   Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products.
Big Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
2 January 2024   District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.
Big Pharma
AstraZeneca prevails in GSK royalties row at UK High Court
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

AIPPI: Personalised medicine tests the limits in patent law
Ropes & Gray loses 21-attorney group to join rival on growth spree
How 'Boehringer' sets preliminary relief threshold for generics
‘Whose trademark law is AI based on exactly?’: Key questions from Marques
The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths